Navigation Links
A major step toward a more targeted treatment for auto-immune diseases?
Date:1/27/2008

More and more people in Western society are suffering from auto-immune diseases. Discovering the cause of these chronic inflammations is a first important step in the search for targeted medicines. VIB researchers connected to Ghent University and the Katholieke Universiteit Leuven joined forces and have elucidated the function of MALT1, a key player in controlling inflammatory reactions. They are the first to show that MALT1 is able to cleave the A20 protein, which inhibits inflammation. Scientists hope that by counteracting MALT1 they will be able to restore the bodys natural inhibition of inflammation and thus provide an alternative for treatments that tax the immune system. This would represent a profound improvement over current medicines. Their research will be published in the authoritative journal Nature Immunology.

Raging out of control?

Inflammations are our normal protective reactions against infections − they arise to help remove pathogenic organisms from our bodies. This immune response is very precise and is only possible after a complex cascade of signals. Sometimes something goes wrong in this chain of reactions, and the inflammation process becomes uncontrolled or even triggers undesired immune responses against the bodys own substances. This can lead to auto-immune diseases such as rheumatism, Crohns disease, psoriasis, and multiple sclerosis, and, in some cases, to cancer. Reining in the runaway immune system is the most obvious remedy for these kinds of diseases. But the major challenge is to do this in such a way that the immune system continues to perform its protective role. And this requires a thorough understanding of the entire process.

Proteins with a crucial function

It has long been known that the MALT1 protein plays an important role in initiating inflammation reactions. Thats why VIB researchers Beatrice Coornaert (UGent), Rudi Beyaert (UGent), Thijs Baens (K.U.Leuven) and Peter Mary
'/>"/>

Contact: Sooike Stoops
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Page: 1 2

Related medicine news :

1. ONDCP Launches First Major Initiative to Combat Teen Prescription Drug Abuse
2. Vendormate Storms into 2008 with Major Milestones for Hospital Vendor Compliance
3. Mini stress tests could help condition heart to survive major attack
4. Food and Drug Law Institute Sponsors Major Enforcement Conference
5. Delta Dental of Illinois Announces Major Gift to University of Illinois at Chicago College of Dentistry
6. ESA and EC take major step forward in GMES
7. CDI-Life Sciences Selected by CJ CheilJedang Corp. to Provide Engineering Design for Major Pharmaceutical Complex in Korea
8. Youth Impacted By Recent Mitchell Report on Major League Baseball Steroid Abuse
9. Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy
10. Venlafaxine extended-release effective for patients with major depression
11. Overwhelming Majority of Michigan Residents Favors Individual Health Insurance Market Reforms Supported by Blue Cross Blue Shield of Michigan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Santa Barbara, CA (PRWEB) October 31, 2014 ... for holiday shoppers to find affordable but tasteful gifts for ... special 22nd Annual Early Bird Gift Giving Special , ... percent off when they purchase Wine Club Gift membership. ... to take advantage of this special. Besides offering discounts, Gold ...
(Date:10/31/2014)... 2014 The Suspension Revolution review published ... was developed by Dan Long, a suspension training specialist. ... fitness professional and life coach. The author of this ... muscles is not impossible , The Suspension Revolution review ... Suspension training promises efficiency when it comes to burning ...
(Date:10/31/2014)... October 31, 2014 North Shore Eye ... Garden City, Long Island and the addition of leading ... staff, according to North Shore Eye Care Medical Director, ... Acting Chairman of the Department of Ophthalmology of Winthrop-University ... in Garden City for more than 30 years. He ...
(Date:10/31/2014)... Beach, Florida (PRWEB) October 31, 2014 ... or, the “Company”) today announced it has signed a ... Canada-based companies in the urban cultivation sector - Urban ... (BC Northern Lights”), and W3 Metal Inc. (“W3 Metal” ... the “Target Companies”). Pursuant to the LOI and ...
(Date:10/31/2014)... RESEARCH UK scientists have found a drug combination that ... - paving the way for new treatments, according to ... Research Institute (NCRI) Cancer Conference in Liverpool next week*. ... initiate a chain of events culminating in self destruction. ... and become immortal. This means that cells grow out ...
Breaking Medicine News(10 mins):Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... cancer of the eye need not have to remove their ... The results of the Collaborative ocular Melanoma ... found that survival rates were the same regardless of whether ... radiation therapy.// , Davidorf, Professor ...
... affects women in their 30s and 40s, especially women.The illness ... cause pain, inflammation and joint destruction. , ... condition, but one third of the patients discontinue treatment early ... taking Methotrexate are prone for their drug-related liver damage .This ...
... exercise can improve their health or it would not make a ... Consensus statements published by the American College of ... researchers often can't tell how much health-improvement pay-off will result from ... make a difference at all. , , ...
... levels is becoming an increasingly important part of a medical ... or 'good' cholesterol) levels should be high, and low density ... At Johns Hopkins ... to measure non-HDL cholesterol too. This is the difference between ...
... to kill the deadly Hepatitis E virus has been designed by ... would kill the virus by cutting RNA. , , ... animals. The cloned virus could also be used for diagnostic purposes ... For this, the team had produced ...
... in tomato products, such as tomato sauce and ketchup, have ... especially prostate cancer, but the reason for such an action ... that lycopene, which is found in tomato products and other ... and treating the disease in its earliest stages.// ...
Cached Medicine News:Health News:How much can exercise improve health? 2Health News:Protective effects of tomatoes in prostate cancer 2
(Date:10/31/2014)... , Oct. 31, 2014  Zebra Imaging, ... visualization technologies announced today a strategic partnership with ... in high-end 3D anatomy and biomedical models for ... and medical education markets.  Zygote maintains the world,s ... biomedical models and has pioneered development of high-end ...
(Date:10/31/2014)... JERUSALEM , October 31, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... the company will host a conference call to ... clinical trial of ORMD-0801, the company,s proprietary oral ... Monday, November 3, 2014 at 10:00 a.m. Eastern ...
(Date:10/31/2014)... 31, 2014  Zacks.com announces the list of stocks featured in ... the latest news and events impacting stocks and the financial markets. ... AMGN - Free Report ), Celgene (Nasdaq: CELG ... - Free Report ), Market Vectors Biotech ETF (AMEX: ... ETF (AMEX: XBI - Free Report ). ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... Oritavancin Studies Presented at ECCMID/ICC, MUNICH, Germany, ... announced results from two studies showing the,improved ... in vitro,when tested with a common wetting ... activity of oritavancin against S.,pneumoniae in a ...
... 04, 2007 /PRNewswire-FirstCall/ -- Celgene,Corporation announced that ... that its Data Monitoring Committee's (DMC),review of ... for patients with newly diagnosed multiple myeloma ... dose of dexamethasone (Decadron) in,combination with lenalidomide ...
Cached Medicine Technology:Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7
A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
... L.E.D. is mounted coaxially on the loupe ... battery pack giving 4 hours continuous use. ... and a charging unit that can hold ... as being a convenient container to keep ...
The PDM utilizes the latest technology for measuring interpupillary distance and left/right pupil-to-nose distance. Lightweight and easy-to-use, the PDM provides accurate and repeatable PD measuremen...
Inquire...
Medicine Products: